| Year |
Citation |
Score |
| 2023 |
Dehner CA, Lo YC, Chopra S, Demicco EG, He K, Hirbe AC, Folpe AL, Chrisinger JSA. CSF1 expression in xanthogranulomatous epithelial tumor/keratin-positive giant cell-rich tumor. Human Pathology. 143: 1-4. PMID 37993023 DOI: 10.1016/j.humpath.2023.11.006 |
0.325 |
|
| 2023 |
Wang J, Calizo A, Zhang L, Pino JC, Lyu Y, Pollard K, Zhang X, Larsson AT, Conniff E, Llosa N, Wood DK, Largaespada DA, Moody SE, Gosline SJ, Hirbe AC, et al. CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon restoration of RB function in malignant peripheral nerve sheath tumors. Biorxiv : the Preprint Server For Biology. PMID 36778419 DOI: 10.1101/2023.02.02.526674 |
0.304 |
|
| 2022 |
Greaney SK, Amin N, Prudner BC, Compernolle M, Sandell LJ, Tebb SC, Weilbaecher KN, Abeln P, Luo J, Tao Y, Hirbe AC, Peterson LL. Yoga Therapy During Chemotherapy for Early-Stage and Locally Advanced Breast Cancer. Integrative Cancer Therapies. 21: 15347354221137285. PMID 36412916 DOI: 10.1177/15347354221137285 |
0.522 |
|
| 2020 |
Hirbe AC, Dodd RD, Pratilas CA. Special Issue: "Genomics and Models of Nerve Sheath Tumors". Genes. 11. PMID 32882803 DOI: 10.3390/Genes11091024 |
0.379 |
|
| 2020 |
Van Handel AC, Galvez MG, Brogan DM, Boyer MI, Cipriano CA, Hirbe AC, Pet MA. Vascularized Ulnar Transposition and Radioulnoscapholunate Fusion With Volar Locking Plate in a Dorsal Position Following Resection of Giant Cell Tumor of the Distal Radius. Techniques in Hand & Upper Extremity Surgery. 24: 142-150. PMID 32841989 DOI: 10.1097/Bth.0000000000000282 |
0.391 |
|
| 2020 |
Monga V, Mani H, Hirbe A, Milhem M. Non-Conventional Treatments for Conventional Chondrosarcoma. Cancers. 12. PMID 32707689 DOI: 10.3390/Cancers12071962 |
0.443 |
|
| 2020 |
Prudner BC, Ball T, Rathore R, Hirbe AC. Diagnosis and management of malignant peripheral nerve sheath tumors: Current practice and future perspectives. Neuro-Oncology Advances. 2: i40-i49. PMID 32642731 DOI: 10.1093/noajnl/vdz047 |
0.31 |
|
| 2020 |
Chrisinger JSA, Wehrli B, Dickson BC, Fasih S, Hirbe AC, Shultz DB, Zadeh G, Gupta AA, Demicco EG. Epithelioid and spindle cell rhabdomyosarcoma with FUS-TFCP2 or EWSR1-TFCP2 fusion: report of two cases. Virchows Archiv : An International Journal of Pathology. PMID 32556562 DOI: 10.1007/S00428-020-02870-0 |
0.504 |
|
| 2020 |
Moon CI, Tompkins W, Wang Y, Godec A, Zhang X, Pipkorn P, Miller CA, Dehner C, Dahiya S, Hirbe AC. Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST. Genes. 11. PMID 32369930 DOI: 10.3390/Genes11050499 |
0.42 |
|
| 2020 |
Miller DT, Cortés-Ciriano I, Pillay N, Hirbe AC, Snuderl M, Bui MM, Piculell K, Al-Ibraheemi A, Dickson BC, Hart J, Jones K, Jordan JT, Kim RH, Lindsay D, Nishida Y, et al. Genomics of MPNST (GeM) Consortium: Rationale and Study Design for Multi-Omic Characterization of NF1-Associated and Sporadic MPNSTs. Genes. 11. PMID 32252413 DOI: 10.3390/Genes11040387 |
0.4 |
|
| 2020 |
Banerjee J, Allaway RJ, Taroni JN, Baker A, Zhang X, Moon CI, Pratilas CA, Blakeley JO, Guinney J, Hirbe A, Greene CS, Gosline SJ. Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1. Genes. 11. PMID 32098059 DOI: 10.3390/Genes11020226 |
0.424 |
|
| 2019 |
Widemann BC, Lu Y, Reinke D, Okuno SH, Meyer CF, Cote GM, Chugh R, Milhem MM, Hirbe AC, Kim A, Turpin B, Pressey JG, Dombi E, Jayaprakash N, Helman LJ, et al. Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016). Sarcoma. 2019: 7656747. PMID 31427883 DOI: 10.1155/2019/7656747 |
0.356 |
|
| 2019 |
Qin W, Godec A, Zhang X, Zhu C, Shao J, Tao Y, Bu X, Hirbe AC. TYK2 promotes malignant peripheral nerve sheath tumor progression through inhibition of cell death. Cancer Medicine. PMID 31278855 DOI: 10.1002/Cam4.2386 |
0.389 |
|
| 2019 |
Prudner BC, Rathore R, Robinson AM, Godec AJ, Chang SF, Hawkins WG, Hirbe AC, Van Tine BA. Arginine Starvation and Docetaxel Induce c-Myc-Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31113844 DOI: 10.1158/1078-0432.Ccr-19-0206 |
0.404 |
|
| 2019 |
Manji GA, Van Tine BA, Lee SM, Raufi A, Patwardhan P, Blumberg LE, Sender N, Wang J, Otap D, Singh-Kandah SV, Do KT, Hirbe AC, Bollag G, Schwartz GK. Phase 1 combination therapy with pexidartinib (PEX) and sirolimus (S) to target tumor-associated macrophages in pigmented villonodular synovitis, malignant peripheral nerve sheath tumors, and other soft tissue sarcomas. Journal of Clinical Oncology. 37: 11055-11055. DOI: 10.1200/Jco.2019.37.15_Suppl.11055 |
0.345 |
|
| 2019 |
Bui N, Dietz H, Hirbe AC, Ganjoo KN, Van Tine BA, Keedy VL, Davis EJ. Multi-institutional analysis of outcomes in patients with dedifferentiated chondrosarcoma (DDCS). Journal of Clinical Oncology. 37: 11028-11028. DOI: 10.1200/Jco.2019.37.15_Suppl.11028 |
0.359 |
|
| 2018 |
Abaricia S, Hirbe AC. Diagnosis and Treatment of Myxoid Liposarcomas: Histology Matters. Current Treatment Options in Oncology. 19: 64. PMID 30362022 DOI: 10.1007/S11864-018-0590-5 |
0.336 |
|
| 2018 |
Lu HC, Eulo V, Apicelli AJ, Pekmezci M, Tao Y, Luo J, Hirbe AC, Dahiya S. Aberrant ATRX protein expression is associated with poor overall survival in NF1-MPNST. Oncotarget. 9: 23018-23028. PMID 29796169 DOI: 10.18632/Oncotarget.25195 |
0.346 |
|
| 2018 |
Hirbe AC, Zhang X, Dahiya S, Godec A, Chrisinger J, Tao Y, Luo J, Gutmann DH. β-III-spectrin immunohistochemistry as a potential diagnostic tool with high sensitivity for malignant peripheral nerve sheath tumors. Neuro-Oncology. PMID 29596596 DOI: 10.1093/Neuonc/Noy038 |
0.316 |
|
| 2018 |
Hirbe AC, Jennings J, Saad N, Giardina JD, Tao Y, Luo J, Berry S, Toeniskoetter J, Van Tine BA. A Phase II Study of Tumor Ablation in Patients with Metastatic Sarcoma Stable on Chemotherapy. The Oncologist. PMID 29487221 DOI: 10.1634/Theoncologist.2017-0536 |
0.345 |
|
| 2017 |
Oppelt PJ, Hirbe AC, Van Tine BA. Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review. Journal of Gastrointestinal Oncology. 8: 466-473. PMID 28736634 DOI: 10.21037/Jgo.2016.09.15 |
0.327 |
|
| 2017 |
Hirbe AC, Cosper PF, Dahiya S, Van Tine BA. Neoadjuvant Ifosfamide and Epirubicin in the Treatment of Malignant Peripheral Nerve Sheath Tumors. Sarcoma. 2017: 3761292. PMID 28546782 DOI: 10.1155/2017/3761292 |
0.389 |
|
| 2017 |
Hirbe AC, Gutmann DH. The management of neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors: challenges, progress, and future prospects Expert Opinion On Orphan Drugs. 5: 623-631. DOI: 10.1080/21678707.2017.1348294 |
0.415 |
|
| 2016 |
Hirbe AC, Kaushal M, Sharma MK, Dahiya S, Pekmezci M, Perry A, Gutmann DH. Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Cancer. PMID 27875628 DOI: 10.1002/Cncr.30455 |
0.356 |
|
| 2016 |
Hirbe AC, Dahiya S, Friedmann-Morvinski D, Verma IM, Clapp DW, Gutmann DH. Spatially- and temporally-controlled postnatal p53 knockdown cooperates with embryonic Schwann cell precursor Nf1 gene loss to promote malignant peripheral nerve sheath tumor formation. Oncotarget. PMID 26859681 DOI: 10.18632/Oncotarget.7232 |
0.393 |
|
| 2015 |
Hirbe AC, Dahiya S, Miller CA, Li T, Fulton RS, Zhang X, McDonald S, DeSchryver K, Duncavage EJ, Walrath J, Reilly KM, Abel HJ, Pekmezci M, Perry A, Ley TJ, et al. Whole Exome Sequencing Reveals the Order of Genetic Changes during Malignant Transformation and Metastasis in a Single Patient with NF1-plexiform Neurofibroma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 25925892 DOI: 10.1158/1078-0432.Ccr-14-3049 |
0.33 |
|
| 2015 |
Pekmezci M, Reuss DE, Hirbe AC, Dahiya S, Gutmann DH, von Deimling A, Horvai AE, Perry A. Morphologic and immunohistochemical features of malignant peripheral nerve sheath tumors and cellular schwannomas. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 28: 187-200. PMID 25189642 DOI: 10.1038/Modpathol.2014.109 |
0.379 |
|
| 2014 |
Hirbe AC, Pekmezci M, Dahiya S, Apicelli AJ, Van Tine BA, Perry A, Gutmann DH. BRAFV600E mutation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. Neuro-Oncology. 16: 466-7. PMID 24366910 DOI: 10.1093/Neuonc/Not248 |
0.38 |
|
| 2013 |
Frith AE, Hirbe AC, Van Tine BA. Novel pathways and molecular targets for the treatment of sarcoma. Current Oncology Reports. 15: 378-85. PMID 23661264 DOI: 10.1007/S11912-013-0319-3 |
0.431 |
|
| 2012 |
Su X, Floyd DH, Hughes A, Xiang J, Schneider JG, Uluckan O, Heller E, Deng H, Zou W, Craft CS, Wu K, Hirbe AC, Grabowska D, Eagleton MC, Townsley S, et al. The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling. The Journal of Clinical Investigation. 122: 3579-92. PMID 22996695 DOI: 10.1172/Jci38576 |
0.778 |
|
| 2012 |
Zhang K, Kim S, Cremasco V, Hirbe AC, Collins L, Piwnica-Worms D, Novack DV, Weilbaecher K, Faccio R. Correction: CD8 + T cells regulate bone tumor burden independent of osteoclast resorption Cancer Research. 72. DOI: 10.1158/0008-5472.Can-11-3840 |
0.638 |
|
| 2011 |
Zhang K, Kim S, Cremasco V, Hirbe AC, Collins L, Piwnica-Worms D, Novack DV, Weilbaecher K, Faccio R. CD8+ T cells regulate bone tumor burden independent of osteoclast resorption. Cancer Research. 71: 4799-808. PMID 21602433 DOI: 10.1158/0008-5472.Can-10-3922 |
0.713 |
|
| 2010 |
Hirbe AC, Morgan EA, Weilbaecher KN. The CXCR4/SDF-1 chemokine axis: a potential therapeutic target for bone metastases? Current Pharmaceutical Design. 16: 1284-90. PMID 20166978 DOI: 10.2174/138161210791034012 |
0.736 |
|
| 2009 |
Hirbe AC, Roelofs AJ, Floyd DH, Deng H, Becker SN, Lanigan LG, Apicelli AJ, Xu Z, Prior JL, Eagleton MC, Piwnica-Worms D, Rogers MJ, Weilbaecher K. The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts. Bone. 44: 908-16. PMID 19442620 DOI: 10.1016/J.Bone.2009.01.010 |
0.735 |
|
| 2008 |
Vaira S, Johnson T, Hirbe AC, Alhawagri M, Anwisye I, Sammut B, O'Neal J, Zou W, Weilbaecher KN, Faccio R, Novack DV. RelB is the NF-kappaB subunit downstream of NIK responsible for osteoclast differentiation. Proceedings of the National Academy of Sciences of the United States of America. 105: 3897-902. PMID 18322009 DOI: 10.1073/Pnas.0708576105 |
0.681 |
|
| 2008 |
Uluçkan O, Eagleton MC, Floyd DH, Morgan EA, Hirbe AC, Kramer M, Dowland N, Prior JL, Piwnica-Worms D, Jeong SS, Chen R, Weilbaecher K. APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in mice. Journal of Cellular Biochemistry. 104: 1311-23. PMID 18260128 DOI: 10.1002/Jcb.21709 |
0.781 |
|
| 2008 |
Apicelli AJ, Maggi LB, Hirbe AC, Miceli AP, Olanich ME, Schulte-Winkeler CL, Saporita AJ, Kuchenreuther M, Sanchez J, Weilbaecher K, Weber JD. A non-tumor suppressor role for basal p19ARF in maintaining nucleolar structure and function. Molecular and Cellular Biology. 28: 1068-80. PMID 18070929 DOI: 10.1128/Mcb.00484-07 |
0.603 |
|
| 2008 |
Floyd D, Wu K, Hirbe A, Uluckan O, Eagleton M, Conley P, Weilbaecher K. P7. The ADP receptor P2Y12 is expressed in developing osteoclasts and is required for full osteoclast function and tumor associated osteolysis Cancer Treatment Reviews. 34: 15. DOI: 10.1016/J.Ctrv.2008.03.048 |
0.755 |
|
| 2007 |
Hirbe AC, Rubin J, Uluçkan O, Morgan EA, Eagleton MC, Prior JL, Piwnica-Worms D, Weilbaecher KN. Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone. Proceedings of the National Academy of Sciences of the United States of America. 104: 14062-7. PMID 17715292 DOI: 10.1073/Pnas.0705203104 |
0.798 |
|
| 2007 |
Hirbe AC, Uluçkan O, Morgan EA, Eagleton MC, Prior JL, Piwnica-Worms D, Trinkaus K, Apicelli A, Weilbaecher K. Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner. Blood. 109: 3424-31. PMID 17192391 DOI: 10.1182/Blood-2006-09-048686 |
0.796 |
|
| 2006 |
Hirbe A, Morgan EA, Uluçkan O, Weilbaecher K. Skeletal complications of breast cancer therapies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 6309s-6314s. PMID 17062720 DOI: 10.1158/1078-0432.Ccr-06-0652 |
0.732 |
|
| 2005 |
Gauvain KM, Garbow JR, Song SK, Hirbe AC, Weilbaecher K. MRI detection of early bone metastases in B16 mouse melanoma models Clinical and Experimental Metastasis. 22: 403-411. PMID 16283483 DOI: 10.1007/S10585-005-1264-9 |
0.7 |
|
| 2005 |
Gao L, Deng H, Zhao H, Hirbe A, Harding J, Ratner L, Weilbaecher K. HTLV-1 Tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition. Blood. 106: 4294-302. PMID 16118323 DOI: 10.1182/Blood-2005-04-1730 |
0.74 |
|
| 2001 |
Gutmann DH, Hirbe AC, Haipek CA. Functional analysis of neurofibromatosis 2 (NF2) missense mutations Human Molecular Genetics. 10: 1519-1529. PMID 11448944 DOI: 10.1093/Hmg/10.14.1519 |
0.338 |
|
| 2001 |
Gutmann DH, Hirbe AC, Huang ZY, Haipek CA. The Protein 4.1 tumor suppressor, DAL-1, impairs cell motility, but regulates proliferation in a cell-type-specific fashion Neurobiology of Disease. 8: 266-278. PMID 11300722 DOI: 10.1006/Nbdi.2000.0376 |
0.391 |
|
| 1999 |
Strauss BL, Gutmann DH, Dehner LP, Hirbe A, Zhu X, Marley EF, Liapis H. Molecular analysis of malignant triton tumors. Human Pathology. 30: 984-8. PMID 10452514 DOI: 10.1016/S0046-8177(99)90255-1 |
0.414 |
|
| Show low-probability matches. |